AZN - Spark Newswire

5 minute read

The Daily Biotech Pulse: FDA Rejects FibroGen’s Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering

Today, 3:12 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10)

ACAD

1 minute read

FibroGen Shares Are Trading Lower As FDA Shoots Down Roxadustat Application, Asks For Additional Trial

By Vandana Singh

Today, 3:12 PM

The FDA has issued a complete response letter regarding the marketing application for FibroGen Inc’s (NASDAQ:FGEN) roxadustat for anemia of…

ALPMF

1 minute read

AstraZeneca, Daiichi Sankyo’s Enhertu Shows Improved PFS Over Roche’s Kadcyla In Breast Cancer

By Vandana Singh

Today, 3:12 PM

AstraZeneca plc (NASDAQ:AZN) and Daiichi Sankyo Co Ltd (OTC:DSKYF) have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The…

AZN

1 minute read

AstraZeneca’s Forxiga Wins European Approval For Chronic Kidney Disease

By Vandana Singh

Today, 3:12 PM

The European Union has approved AstraZeneca plc’s (NASDAQ:AZN) Forxiga (dapagliflozin) for chronic kidney disease (CKD) in adults with and without type-2…

AZN

10 minute read

FDA
News

AstraZeneca Reports ENHERTU Improved Progression-Free Survival In DESTINY-Breast03 Head-To-Head Trial vs Trastuzumab Emtansine In Patients With HER2

By Benzinga Newsdesk

Today, 3:12 PM

IDMC recommended unblinding based on primary efficacy endpoint demonstrating superiority; results also indicate strong trend toward improved overall survival Plans for global regulatory submission underway Positive

AZN

2 minute read

FDA
News

AstraZeneca Announced Enhertu Significantly Improved Progression-free Survival in DESTINY-breast03 Head-to-head Trial Vs. Trastuzumab Emtansine (T-dm1) in Patients With HER2-positive Metastatic Breast Cancer

By Charles Gross

Today, 3:12 PM

Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial showed that Enhertu (trastuzumab deruxtecan), the AstraZeneca (NYSE: AZN) and Daiichi Sankyo Company, Limited (Daiichi Sankyo) HER2-directed antibody drug conjugate (ADC), demonstrated superiority over trastuzumab emtansine (T-DM1).

AZN

2 minute read

AstraZeneca Announced Forxiga Approved in the EU for Chronic Kidney Disease

By Charles Gross

Today, 3:12 PM

AstraZeneca's (NYSE: AZN) Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D).

AZN

1 minute read

FDA
News

European Medicines Agency On AstraZeneca COVID-19 Vaccine Shot: Side Effects Like Weakness Of Extremities Are ‘Very Rare,’ Benefit-Risk Balance Of AstraZeneca

By Benzinga Newsdesk

Today, 3:12 PM

-Reuters

AZN

1 minute read

Sierra Oncology Bets $216M On AstraZeneca’s BET Inhibitor For Myelofibrosis

By Vandana Singh

Today, 3:12 PM

Sierra Oncology Inc (NASDAQ:SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ:AZN) for AZD5153, a potent, and selective BRD4 BET inhibitor…

AZN

6 minute read

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO

By Shanthi Rexaline

Today, 3:12 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)

ACAD

Feed Symbols: AZN